Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 10/2015

01-10-2015 | Original Paper

Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention

Authors: Marya Gwadz, Charles M. Cleland, Elizabeth Applegate, Mindy Belkin, Monica Gandhi, Nadim Salomon, Angela Banfield, Noelle Leonard, Marion Riedel, Hannah Wolfe, Isaiah Pickens, Kelly Bolger, DeShannon Bowens, David Perlman, Donna Mildvan, The Heart to Heart Collaborative Research Team

Published in: AIDS and Behavior | Issue 10/2015

Login to get access

Abstract

Nationally up to 60 % of persons living with HIV are neither taking antiretroviral therapy (ART) nor well engaged in HIV care, mainly racial/ethnic minorities. This study examined a new culturally targeted multi-component intervention to address emotional, attitudinal, and social/structural barriers to ART initiation and HIV care. Participants (N = 95) were African American/Black and Latino adults with CD4 < 500 cells/mm3 not taking ART, randomized 1:1 to intervention or control arms, the latter receiving treatment as usual. Primary endpoints were adherence, evaluated via ART concentrations in hair samples, and HIV viral load suppression. The intervention was feasible and acceptable. Eight months post-baseline, intervention participants tended to be more likely to evidence “good” (that is, 7 days/week) adherence (60 vs. 26.7 %; p = 0.087; OR = 3.95), and had lower viral load levels than controls (t(22) = 2.29, p = 0.032; OR = 5.20), both large effect sizes. This highly promising intervention merits further study.
Literature
1.
Granich R, Williams B, Montaner J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS. 2013;8(1):41–9.PubMedCrossRef
2.
3.
Buchbinder SP, Liu AY. CROI 2014: new tools to track the epidemic and prevent HIV infections. Top Antivir Med. 2014;22(2):579–93.PubMed
4.
Doshi RK, Malebranche D, Bowleg L, Sangaramoorthy T. Health care and HIV testing experiences among Black men in the South: implications for “Seek, Test, Treat, and Retain” HIV prevention strategies. AIDS Patient Care STDS. 2013;27(2):123–33.PubMedCentralPubMedCrossRef
5.
Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52(Suppl 2):S205–7.PubMedCrossRef
6.
Montague BT, Vuylsteke B, Buve A. Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention. BMC Public Health. 2011;11:701.PubMedCentralPubMedCrossRef
7.
Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59(Suppl 1):S21–7.PubMedCentralPubMedCrossRef
8.
Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCentralPubMedCrossRef
9.
Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs: hIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7.PubMed
10.
11.
Beer L, Fagan JL, Garland P, et al. Medication-related barriers to entering HIV care. AIDS Patient Care STDS. 2012;26(4):214–21.PubMedCentralPubMed
12.
Tobias CR, Cunningham W, Cabral HD, et al. Living with HIV but without medical care: barriers to engagement. AIDS Patient Care STDS. 2007;21(6):426–34.PubMedCrossRef
13.
Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDS. 2002;16(5):233–40.PubMedCrossRef
14.
Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.PubMedCrossRef
15.
Flay BR, Snyder F, Petraitis J. The theory of triadic influence. In: DiClimente RJ, Kegler MC, Crosby RA, editors. Emerging theories in health promotion practice and research. New York: Jossey-Bass; 2009. p. 451–510.
16.
Deci EL, Ryan RM. The “what” and “why” of goal pursuits: human needs and the self-determination of behavior. Psychol Inq. 2000;11(4):227–68.CrossRef
17.
Vansteenkiste M, Sheldon KM. There’s nothing more practical than a good theory: integrating motivational interviewing and self-determination theory. Br J Clin Psychol. 2006;45(Pt 1):63–82.PubMedCrossRef
18.
van Ryn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med Care. 2002;40(1 Suppl):I140–51.PubMed
19.
Whetten K, Leserman J, Whetten R, et al. Exploring lack of trust in care providers and the government as a barrier to health service use. Am J Public Health. 2006;96(4):716–21.PubMedCentralPubMedCrossRef
20.
Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr. 2005;38(2):213–8.PubMedCrossRef
21.
22.
Kreuter MW, Skinner CS, Steger-May K, et al. Responses to behaviorally vs culturally tailored cancer communication among African American women. Am J Health Behav. 2004;28(3):195–207.PubMedCrossRef
23.
Schneider TR, Salovey P, Apanovitch AM, et al. The effects of message framing and ethnic targeting on mammography use among low-income women. Health Psychol. 2001;20(4):256–66.PubMedCrossRef
24.
Barrera M Jr, Castro FG, Strycker LA, Toobert DJ. Cultural adaptations of behavioral health interventions: a progress report. J Consult Clin Psychol. 2013;81(2):196–205.PubMedCentralPubMedCrossRef
25.
Kreuter MW, Lukwago SN, Bucholtz DC, Clark EM, Sanders-Thompson V. Achieving cultural appropriateness in health promotion programs: targeted and tailored approaches. Health Educ Behav. 2003;30(2):133–46.PubMedCrossRef
26.
Fagan JL, Beer L, Garland P, et al. The influence of perceptions of HIV infection, care, and identity on care entry. AIDS Care. 2012;24(6):737–43.PubMedCrossRef
27.
Jenness SM, Myers JE, Neaigus A, Lulek J, Navejas M, Raj-Singh S. Delayed entry into HIV medical care after HIV diagnosis: risk factors and research methods. AIDS Care. 2012;24(10):1240–8.PubMedCrossRef
28.
Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013;27(14):2271–9.PubMedCrossRef
29.
Kalichman SC, Catz S, Ramachandran B. Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 1999;91(8):439–46.PubMedCentralPubMed
30.
Tugenberg T, Ware NC, Wyatt MA. Paradoxical effects of clinician emphasis on adherence to combination antiretroviral therapy for HIV/AIDS. AIDS Patient Care STDS. 2006;20(4):269–74.PubMedCrossRef
31.
Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–55.PubMedCentralPubMed
32.
Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009;21(8):953–66.PubMedCentralPubMedCrossRef
33.
Nordqvist O, Sodergard B, Tully MP, Sonnerborg A, Lindblad AK. Assessing and achieving readiness to initiate HIV medication. Patient Educ Couns. 2006;62(1):21–30.PubMedCrossRef
34.
Alfonso V, Bermbach N, Geller J, Montaner JS. Individual variability in barriers affecting people’s decision to take HAART: a qualitative study identifying barriers to being on HAART. AIDS Patient Care STDS. 2006;20(12):848–57.PubMedCrossRef
35.
Gold RS, Hinchy J, Batrouney CG. The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. Int J STD AIDS. 2000;11(6):361–70.PubMedCrossRef
36.
Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients’ perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45(3):334–41.PubMed
37.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1–34.PubMedCrossRef
38.
Mugavero MJ, Lin HY, Allison JJ, et al. Failure to establish HIV care: characterizing the “no show” phenomenon. Clin Infect Dis. 2007;45(1):127–30.PubMedCrossRef
39.
Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.PubMedCrossRef
40.
Gwadz M, Applegate E, Cleland C, et al. HIV-Infected individuals who delay, decline, or discontinue antiretroviral therapy: comparing clinic- and peer-recruited cohorts. Front Public Health. 2014;2:81.PubMedCentralPubMedCrossRef
41.
Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–73.PubMedCrossRef
42.
Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African-American men with HIV. Ann Behav Med. 2010;40(2):184–90.PubMedCentralPubMedCrossRef
43.
44.
Owen-Smith A, McCarty F, Hankerson-Dyson D, Diclemente R. Prevalence and predictors of complementary and alternative medicine use in African-Americans with acquired immune deficiency syndrome. Focus Altern Complement Ther. 2012;17(1):33–42.PubMedCentralPubMedCrossRef
45.
Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care. 1999;11(3):361–73.PubMedCrossRef
46.
47.
48.
Rao KC, Enriquez M, Gantt TC, et al. Nonengagement in HIV care: a descriptive and qualitative study in hospitalized patients and community-based analysis. J Int Assoc Provid AIDS Care. 2013;12(3):178–84.PubMedCrossRef
49.
Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–8.PubMedCentralPubMedCrossRef
50.
Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. AIDS. 2000;14(Suppl 1):S3–10.PubMedCrossRef
51.
Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011;52(Suppl 2):S238–46.PubMedCentralPubMedCrossRef
52.
Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav. 2007;11(6 Suppl):101–15.PubMedCrossRef
53.
Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41–6.PubMedCrossRef
54.
Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37(12):1270–81.PubMedCrossRef
55.
Riley ED, Gandhi M, Hare C, Cohen J, Hwang S. Poverty, unstable housing, and HIV infection among women living in the United States. Curr HIV/AIDS Rep. 2007;4(4):181–6.PubMedCrossRef
56.
Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14(3):309–18.PubMedCrossRef
57.
Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008;47(5):597–606.PubMedCrossRef
58.
59.
Miller WR, Rollnick S. Motivational interviewing: helping people change. New York: Guilford Press; 2012.
60.
DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23(2):207–18.PubMedCrossRef
61.
62.
Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. Patient Educ Couns. 2014;94(3):291–309.PubMedCrossRef
63.
Piantadosi S. Clinical trials: a methodological perspective. New York: Wiley; 2005.CrossRef
64.
Liu AY, Yang QY, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). Plos One. 2014;9(1):e83736.PubMedCentralPubMedCrossRef
65.
66.
Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(21):3401–9.PubMedCentralPubMedCrossRef
67.
Huang Y, Yang Q, Yoon K, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;401(6):1923–33.PubMedCentralPubMedCrossRef
68.
Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66(3):311–5.PubMedCentralPubMedCrossRef
69.
Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–75.PubMedCentralPubMedCrossRef
70.
71.
Shapiro M, Morton S, McCaffrey D, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281(24):2305–15.PubMedCrossRef
72.
Huba GJ, Melchior LA, Staff of the Measurement Group, HRSA/HAB’s SPNS Cooperative Agreement Steering Committee. Module 26B:CES-D8 Form. Culver City: The Measurement Group, 1995. Available at: www.​TheMeasurementGr​oup.​com.
73.
Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–12.PubMedCrossRef
74.
Huba GJ, Melchior LA, Staff of the Measurement Group, HRSA/HAB’s SPNS Cooperative Agreement Steering Committee. Module 11: Client Satisfaction Survey. Culver City: The Measurement Group, 1997. Available at: www.​TheMeasurementGr​oup.​com.
75.
Beumer JH, Bosman IJ, Maes R. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract. 2001;55(6):353–7.PubMed
76.
Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18(7):853–61.PubMedCentralPubMedCrossRef
77.
Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71.PubMedCrossRef
78.
79.
Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19(22):3127–31.PubMedCrossRef
80.
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
81.
Wagner GJ, Lovely P, Schneider S. Pilot controlled trial of the adherence readiness program: an intervention to assess and sustain HIV antiretroviral adherence readiness. AIDS Behav. 2013;17(9):3059–65.PubMedCrossRef
82.
Kalichman SC, Cherry C, Kalichman MO, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health. 2011;101(3):531–8.PubMedCentralPubMedCrossRef
83.
Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46(4):443–50.PubMedCentralPubMedCrossRef
84.
Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515–21.PubMedCentralPubMedCrossRef
85.
Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012;9(4):313–25.PubMedCrossRef
86.
Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.PubMedCentralPubMedCrossRef
87.
Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24(11):1448–52.PubMedCrossRef
88.
Johnson BT, Michie S, Snyder LB. Effects of behavioral intervention content on HIV prevention outcomes: a meta-review of meta-analyses. J Acquir Immune Defic Syndr. 2014;66(Suppl 3):S259–70.PubMedCrossRef
89.
Koenig LJ, Pals SL, Bush T, Pratt Palmore M, Stratford D, Ellerbrock TV. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychol. 2008;27(2):159–69.PubMedCrossRef
90.
Holstad MM, DiIorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav. 2011;15(5):885–96.PubMedCentralPubMedCrossRef
91.
Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44–51.PubMedCentralPubMedCrossRef
92.
Kemppainen JK, Holzemer WL, Nokes K, et al. Self-care management of anxiety and fear in HIV disease. J Assoc Nurses AIDS Care. 2003;14(2):21–9.PubMedCrossRef
93.
94.
Öhman A. Fear and anxiety: evolutionary, cognitive, and clinical perspectives. In: Haviland-Jones MLJM, editor. Handbook of emotions. New York: The Guilford Press; 2000. p. 573–93.
95.
Gray JA. The neuropsychology of anxiety. Oxford: Oxford University Press; 1982.
96.
Turner MM. Using emotional appeals in health messages. In: Cho H, editor. Health communication message design. Thousand Oaks: Sage Publications, Inc.; 2012. p. 59–73.
97.
Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059–67.PubMedCrossRef
98.
Deci EL, Ryan RM. Self-determination theory: a macrotheory of human motivation, development, and health. Can Psychol. 2008;49(3):182.CrossRef
99.
Vansteenkiste M, Williams GC, Resnicow K. Toward systematic integration between self-determination theory and motivational interviewing as examples of top-down and bottom-up intervention development: autonomy or volition as a fundamental theoretical principle. Int J Behav Nutr Phys Act. 2012;9:23.PubMedCentralPubMedCrossRef
100.
101.
102.
Bradford JB, Coleman S, Cunningham W. HIV System Navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21(Suppl 1):S49–58.PubMed
103.
Liau A, Crepaz N, Lyles CM, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996–2011. AIDS Behav. 2013;17(6):1941–62.PubMedCrossRef
104.
Kim JJ, Maulsby C, Kinsky S, et al. The development and implementation of the national evaluation strategy of access to care, a multi-site linkage to care initiative in the United States. AIDS Educ Prev. 2014;26(5):429–44.PubMedCrossRef
105.
Holmes-Rovner M, Kroll J, Schmitt N, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Mak. 1996;16(1):58–64.CrossRef
106.
Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011(10):CD001431.
107.
Wills CE, Holmes-Rovner M. Integrating decision making and mental health interventions research: research directions. Clin Psychol. 2006;13(1):9–25.
108.
Shechter SM, Bailey MD, Schaefer AJ, Roberts MS. The optimal time to initiate HIV therapy under ordered health states. Oper Res. 2008;56(1):20–33.CrossRef
109.
110.
Mohareb AM, Rothman RE, Hsieh YH. Emergency department (ED) utilization by HIV-infected ED patients in the United States in 2009 and 2010: a national estimation. HIV Med. 2013;14(10):605–13.PubMedCrossRef
111.
Parashar S, Chan K, Milan D, et al. The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting. AIDS Care. 2014;26(1):53–64.PubMedCentralPubMedCrossRef
Metadata
Title
Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention
Authors
Marya Gwadz
Charles M. Cleland
Elizabeth Applegate
Mindy Belkin
Monica Gandhi
Nadim Salomon
Angela Banfield
Noelle Leonard
Marion Riedel
Hannah Wolfe
Isaiah Pickens
Kelly Bolger
DeShannon Bowens
David Perlman
Donna Mildvan
The Heart to Heart Collaborative Research Team
Publication date
01-10-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 10/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1054-6

Other articles of this Issue 10/2015

AIDS and Behavior 10/2015 Go to the issue

Original Paper

The Influence of a Peer-Based HIV Prevention Intervention on Conversation About HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland

Brief Report

iTunes Song-Gifting is a Low-Cost, Efficient Recruitment Tool to Engage High-Risk MSM in Internet Research

Original Paper

Acceptability and Preliminary Efficacy of a Tailored Online HIV/STI Testing Intervention for Young Men who have Sex with Men: The Get Connected! Program

Original Paper

Teachers’ Patterns of Implementation of an Evidence-Based Intervention and Their Impact on Student Outcomes: Results from a Nationwide Dissemination over 24-Months Follow-Up

Original Paper

Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States

Original Paper

Evaluation of a Socio-cultural Intervention to Reduce Unprotected Sex for HIV Among African American/Black Women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits